The association between chemotherapy-induced febrile neutropenia and breast cancer subtype in Japanese patients.
Breast cancer
Chemotherapy
Febrile neutropenia
Risk factor
Subtype
Journal
International journal of clinical pharmacy
ISSN: 2210-7711
Titre abrégé: Int J Clin Pharm
Pays: Netherlands
ID NLM: 101554912
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
04
06
2019
accepted:
11
12
2019
pubmed:
23
12
2019
medline:
22
1
2021
entrez:
23
12
2019
Statut:
ppublish
Résumé
Background Chemotherapy-induced febrile neutropenia is a common and potentially lethal side effect; therefore, predicting febrile neutropenia development is important. Objective This study examined the risk factors for febrile neutropenia development according to breast cancer subtype among Japanese patients receiving chemotherapy. Methods This single-center retrospective study evaluated 60 outpatients who received chemotherapy for breast cancer (epirubicin plus cyclophosphamide or docetaxel plus cyclophosphamide). Their characteristics were evaluated to identify factors associated with febrile neutropenia development. Results Thirty-three patients developed febrile neutropenia and 27 patients did not. The risk of developing febrile neutropenia was significantly associated with estrogen receptor negativity (p < 0.05). Logistic regression analysis further confirmed that estrogen receptor negativity was an independent risk factor for febrile neutropenia development (odds ratio: 4.35, 95% confidence interval: 1.05-18.0). Moreover, the highest rate of febrile neutropenia was observed in patients with hormone receptor (estrogen and/or progesterone receptor)-negative/human epidermal growth factor receptor 2-positive breast cancer. Conclusion In addition to the known risk factors for febrile neutropenia, our findings revealed that the risk of developing chemotherapy-induced febrile neutropenia is associated with the hormone receptor-negative/human epidermal growth factor receptor 2-positive subtype in Japanese patients with breast cancer.
Identifiants
pubmed: 31865592
doi: 10.1007/s11096-019-00952-x
pii: 10.1007/s11096-019-00952-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7-10Références
Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors. Eur J Cancer. 2006;42:2433–53.
doi: 10.1016/j.ejca.2006.05.002
Kasi PM, Grothey A. Chemotherapy-induced neutropenia as a prognostic and predictive marker of outcomes in solid-tumor patients. Drugs. 2018;78:737–45.
doi: 10.1007/s40265-018-0909-3
Lyman GH, Poniewierski MS. A patient risk model of chemotherapy-induced febrile neutropenia: lessons learned from the ANC study group. J Natl Compr Canc Netw. 2017;15:1543–50.
doi: 10.6004/jnccn.2017.7038
Chen K, Zhang X, Deng H, Zhu L, Su F, Jia W, et al. Clinical predictive models for chemotherapy-induced febrile neutropenia in breast cancer patients: a validation study. PLoS ONE. 2014;9:e96413.
doi: 10.1371/journal.pone.0096413
Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, et al. Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat. 2008;110:531–9.
doi: 10.1007/s10549-007-9744-z
Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48:3342–54.
doi: 10.1016/j.ejca.2012.05.023
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
doi: 10.1038/bmt.2012.244
Azuma Y, Hata K, Sai K, Udagawa R, Hirakawa A, Tohkin M, et al. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer. Biol Pharm Bull. 2012;35:717–24.
doi: 10.1248/bpb.35.717
Hofheinz RD, Heinemann V, von Weikersthal LF, Laubender RP, Gencer D, Burkholder I, et al. Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. Br J Cancer. 2012;107:1678–83.
doi: 10.1038/bjc.2012.434
Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, et al. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. J Clin Oncol. 2013;31:4283–9.
doi: 10.1200/JCO.2012.48.3644